Novo Nordisk A/S (NVO) Could Lose To Eli Lilly, Warns Jim Cramer

We recently published 10 Stocks That Jim Cramer Talked About. Novo Nordisk A/S (NYSE:NVO) is one of the stocks Jim Cramer recently discussed.

Novo Nordisk A/S (NYSE:NVO) came up during the show in the context of trade discussions between the US and Europe and potential tariffs on the pharmaceutical sector. For context, Novo Nordisk A/S (NYSE:NVO) is among the few firms in the world that can compete with Eli Lilly in the weight loss drug market. Cramer’s previous remarks about the firm have wondered why Novo Nordisk A/S (NYSE:NVO) has lost the lead in the weight loss drug market despite introducing the product first. This time, he discussed the dynamics of the market:

“[If market should start thinking about sectoral tariffs after Trump’s latest remarks] I mean when I heard it first I said okay, so they put a tariff on Novo Nordisk. It’s really good for Eli Lilly. Now that’s not necessarily what we’re talking about but remember this price differential right now. . CVS, Eli Lilly versus Novo. So for Wegovy versus Zepbound. Be interesting to see what happens, I think it’s very bullish for Eli Lilly.

“Novo’s trying to move here fast.”

Here’s what Cramer said earlier about Novo Nordisk A/S (NYSE:NVO) and tariffs:

“I want you to know I don’t want Novo Nordisk… and the reason that is because if there’s going to be talk about tariffs on foreign drugs versus Eli Lilly, Novo is going to have an even less of an edge on this thing. So I say Novo, we don’t need the bottom finish. It’s not for me.”

While we acknowledge the potential of NVO as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an extremely cheap AI stock that is also a major beneficiary of Trump tariffs and onshoring, see our free report on the best short-term AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.